
	Where results make sense

Topic: Bortezomib

In the News (Thu 31 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	MedlinePlus Drug Information: Bortezomib (Systemic) (Site not responding. Last check: 2007-10-10)
		Bortezomib interferes with the growth of cancer cells, which are then eventually destroyed by the body.
		Bortezomib is to be administered only by or under the supervision of your doctor.
		For longer treatment of more than 8 cycles, bortezomib may be taken on the regular schedule or on a maintenance schedule of once a week for 4 weeks (days 1, 8, 15, and 22) followed by a 13-day rest period (days 23–35).
	www.nlm.nih.gov /medlineplus/druginfo/uspdi/500475.html (1338 words)

	Bortezomib Delays Progression of Multiple Myeloma - National Cancer Institute
		Early results dramatically favored bortezomib, and thus a companion study was launched where patients in the dexamethasone group were switched to bortezomib as soon as their disease began to progress.
		Those taking bortezomib reduced their risk of dying by 43 percent, with a one-year survival rate of 80 percent compared to 66 percent for those taking dexamethasone.
		Side effects were a greater problem in the bortezomib group, forcing 121 (37 percent) of them to withdraw from the study compared to 96 (29 percent) who had to withdraw from the dexamethasone group.
	www.cancer.gov /clinicaltrials/results/bortezomib0604 (1169 words)

	Cancer Cell International \| Full text \| Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
		Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for single-agent use in the treatment of patients with multiple myeloma who have received at least 2 prior therapies and are progressing on their most recent therapy.
		Bortezomib, a boronic acid dipeptide (Figure 1A) [12], is a highly selective, reversible inhibitor of the 26S proteasome that was first shown to exhibit antitumor properties in a panel of 60 cancer cell lines from the US National Cancer Institute [13].
		Finally, the researchers showed that bortezomib was not only directly cytotoxic to the multiple myeloma cells but that it also altered the microenvironment through inhibition of IL-6 to prevent the growth of tumor cells in proximity to the bone marrow [15].
	www.cancerci.com /content/5/1/18 (5184 words)

	BioMed Central \| Full text \| Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in ...
		Bortezomib is a reversible inhibitor of the proteasome.
		The patient we report here was included in a dose-finding study of bortezomib combined with cisplatin-gemcitabine chemotherapy in first-line treatment of patients with advanced solid tumors [5].
		This study did not show a negative impact of bortezomib on the incidence of congestive heart failure, which was comparable in both arms at 2 percent [13].
	www.biomedcentral.com /1471-2407/6/129 (2364 words)

	Bortezomib
		Bortezomib is the first in a new class of anticancer agents known as proteasome inhibitors, for injection for the treatment of multiple myeloma.
		This agent is a reversible proteasome inhibitor that appears to act directly on the myeloma and the bone microenvironment to inhibit the growth and survival of the myeloma.
		Bortezomib for the treatment of multiple myeloma is considered medically necessary if the medical appropriateness criteria are met.
	www.bcbst.com /MPManual/Bortezomib.htm (637 words)

	bortezomib side effects (Site not responding. Last check: 2007-10-10)
		Bortezomib should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
		Bortezomib is used in the treatment of the blood cancer multiple myeloma.
		Bortezomib is in the FDA pregnancy category D. This means that it is known to be harmful to an unborn baby.
	www.medicationadvisor.com /side_effects/bortezomib.htm (1865 words)

	Newly Approved Drug Therapies (830): Velcade (bortezomib), Millennium Pharmaceuticals
		Based on preclinical studies, bortezomib seems to be cytotoxic to a variety of cancer cell types in vitro.
		Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.
		The compound bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells.
	www.centerwatch.com /patient/drugs/dru830.html (671 words)

	Bortezomib and Velcade Chemotherapy Drugs
		The amount of bortezomib that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated.
		Before starting bortezomib treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
		Proteasome is part of the cellular machinery and has many functions within the cell, such as it helps to control the level of many of the proteins that help to regulate cell division and cell survival.
	www.chemocare.com /bio/bortezomib.asp (1406 words)

	A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma -- San Miguel et al. 11 (1): 51 -- ...
		of bortezomib in the presence of renal impairment.
		Bortezomib is more effective than high-dose dexamethasone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma.
		Bortezomib causes tumorlys is syndrome in approximately 1% of patients with myeloma.
	theoncologist.alphamedpress.org /cgi/content/full/11/1/51 (4925 words)

	CiteULike: Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ... (Site not responding. Last check: 2007-10-10)
		Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor.
		Although the proteasome is clearly its locus of action, the early biochemical consequences of bortezomib treatment are poorly defined.
		Inhibition of thiolesterification correlated with a reduction in the ubiquitination of certain substrates, exemplified by a dramatic decline in histone monoubiquitination and a decrease in the rate of inositol 1,4,5-trisphosphate receptor polyubiquitination.
	www.citeulike.org /user/caroline/article/850828 (333 words)

	Bortezomib - Wikipedia, the free encyclopedia
		Bortezomib (originally PS-341 and marketed as Velcade™ by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans.
		The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity.
		Bortezomib is associated with peripheral neuropathy in 30% of patients; occasionally, it can be painful.
	en.wikipedia.org /wiki/Bortezomib (327 words)

	Velcade (Bortezomib)
		Velcade is being used as a third-line therapy - that is, it is being given to patients who have received at least two other forms of therapy without resolution of their disease.
		This does not represent the final recommendation by NICE on use of Velcade; it is the current proposal and is subject to modification based on responses to the ACD.
		Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers
	www.lrf.org.uk /en/1/disvelstd.html (439 words)

	Bortezomib extends lung cancer survival
		Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial led by UC Davis Cancer Center.
		In the study, patients taking bortezomib plus gemcitabine and carboplatin had a median survival of 11 months, reported Angela Davies, an assistant professor of hematology and oncology at UC Davis Cancer Center and lead author of the study.
		Bortezomib, sold under the trade name Velcade, is a small-molecule proteasome inhibitor originally approved as a treatment for multiple myeloma.
	www.news-medical.net /?id=18392 (477 words)

	Research shows bortezomib benefits a third of multiple myeloma patients
		CHAPEL HILL -- Bortezomib, a new cancer-fighting drug also called Velcade, shows promise for treating patients whose multiple myeloma no longer responds to conventional chemotherapy, a new clinical study concludes.
		About 35 percent of 193 relapsed patients treated in the multi-center phase 2 clinical trial responded positively to the compound, researchers found, including seven whose myeloma protein became undetectable and 12 whose telltale protein could be found only with a special test called immunofixation.
		Bortezomib, formerly known as PS-341, has shown special promise in the treatment of myeloma, Orlowski said.
	www.eurekalert.org /pub_releases/2003-06/uonc-rsb062403.php (754 words)

	Drug Interactions between the Proteasome Inhibitor Bortezomib and Cytotoxic Chemotherapy, Tumor Necrosis Factor (TNF) ...
		Cells were subsequently treated with bortezomib or vehicle control for 48 h before harvesting cells for assessment of apoptosis by annexin V-FITC staining.
		alone or in combination with bortezomib or appropriate vehicle controls were added at the indicated concentrations for 48 h, and cell viability was measured by the MTT assay.
		Chemotherapy (doxor, doxorubicin; pacl, paclitaxel; vinb, vinblastine), bortezomib, or appropriate vehicle controls were added at the indicated concentrations for 48 h, and cell viability was measured by the MTT assay.
	clincancerres.aacrjournals.org /cgi/content/full/9/12/4537 (4144 words)

	Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib - Nature Methods (Site not responding. Last check: 2007-10-10)
		Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as important tools in the treatment of the fatal hematologic malignancy multiple myeloma.
		Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myeloma, many of the basic pharmacologic parameters of bortezomib and its mode of action on myeloma cells remain to be determined.
		Bortezomib was previously reported to be a specific inhibitor for the chymotryptic-like activity largely provided by the
	www.nature.com /nmeth/journal/v2/n5/full/nmeth759.html (4360 words)

	Multiple myeloma - bortezomib: Appraisal consultation document
		Bortezomib (Janssen-Cilag Ltd) is an anticancer drug that belongs to a novel class of drugs known as proteasome inhibitors.
		Bortezomib has a UK marketing authorisation as monotherapy for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have undergone, or are unsuitable for, bone marrow transplantation.
		The Committee considered it important that the position of bortezomib in the clinical management of multiple myeloma should continue to be established by ongoing and planned clinical trials that compare bortezomib with other treatments that are used in the NHS in England and Wales.
	www.nice.org.uk /page.aspx?o=344008 (3673 words)

	Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel ... (Site not responding. Last check: 2007-10-10)
		After exposure, the cell survivals were assessed by a MTT assay (A), or the cells were exposed to different concentrations of bortezomib for 48 h.
		After 24 h of incubation, the cells were taken from cultures and stained with propidium iodide for the determination of apoptosis by FACS analysis.
		Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
	www.jbc.org /cgi/content/full/278/36/33714 (5910 words)

	Bortezomib - National Cancer Institute
		Bortezomib is approved by the Food and Drug Administration (FDA) to treat multiple myeloma that has gotten worse during treatment with other anticancer drugs.
		Bortezomib is also being studied in the treatment of other types of cancer.
		FDA Approval for Bortezomib - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
	www.cancer.gov /cancertopics/druginfo/bortezomib (443 words)

	NEJM -- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
		bortezomib in a companion study after disease progression.
		Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
		Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
	content.nejm.org /cgi/content/short/352/24/2487 (1315 words)

	The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins ...
		The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim -- Nikrad et al.
		Cells were incubated with 1 µmol/L bortezomib or vehicle for 17 h, lysed, and prepared for Western blot analysis with the indicated antibodies.
		C, MEF were incubated with 1 µmol/L bortezomib for 4 h and processed for Western blotting for Bim and GAPDH as a loading control.
	mct.aacrjournals.org /cgi/content/full/4/3/443 (4818 words)

	CancerQuest : Closer Look : Proteasomes
		Bortezomib is also a poor substrate for drug efflux pumps such as MDR.
		Bortezomib may work well in conjunction with other chemotherapy drugs.
		Bortezomib seems to work especially well when used with other chemotherapy drugs because it inhibits the ability of the cancer cells to protect themselves against chemotherapy damage.
	www.cancerquest.org /index.cfm?page=352 (145 words)

	Bortezomib (Systemic) - MayoClinic.com (Site not responding. Last check: 2007-10-10)
		There is a chance that this medicine may cause birth defects if it is taken by the mother during pregnancy.
		Because bortezomib may cause serious side effects in the breast-fed baby, breast-feeding is generally not recommended while you are receiving this medicine.
		Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of bortezomib in children with use in other age groups.
	www.mayoclinic.com /health/drug-information/DR500475 (1354 words)

	Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with ...
		Bortezomib induces high levels of apoptosis in CLL cells.
		bortezomib, and apoptosis was measured by PI staining and FACS analysis.
		Cells were incubated for 24 or 48 h with bortezomib, and DNA fragmentation was measured by PI-FACS.
	clincancerres.aacrjournals.org /cgi/content/full/9/12/4570 (3755 words)

	Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed ... (Site not responding. Last check: 2007-10-10)
		Bortezomib protected mice from GVHD mortality when administration was daily from day 0 through +2 after BMT.
		In contrast, the small intestines from mice with delayed bortezomib treatment (B-C) have villous blunting and fusion (v), hyperplastic crypts (c), and an inflammatory infiltrate (arrow).
		In contrast, colons from mice with delayed bortezomib treatment have increased (E) goblet cell depletion and inflammatory cells (arrow) in the lamina propria.
	www.bloodjournal.org /cgi/content/full/106/9/3293 (4577 words)

	Millennium \| Research and Development \| Oncology \| Development Candidates \| VELCADE
		(bortezomib) for Injection is indicated for the treatment of multiple myeloma patients who have received at least 1 prior therapy.
		VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.
		VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
	www.mlnm.com /rd/oncology/candidates/velcade.asp (903 words)

	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple ...
		PK + bortezomib does not affect the viability of patient MM-derived bone marrow stroma cells (BMSCs) and overcome the antiapoptotic effects of interleukin-6 (IL-6) or insulin growth factor-1 (IGF-1).
		MM.1S cells were treated with PK + bortezomib alone or in the presence of caspase-8 inhibitor, caspase-9 inhibitor, or pan–caspase-3 inhibitor for 24 hours; harvested; and assessed for viability using MTT assays.
		PK and bortezomib treatment triggers activation of c-Jun NH3-terminal kinase (JNK) and translocation of JNK from cytosol to mitochondria in MM.1S MM cells.
	www.bloodjournal.org /cgi/content/full/104/8/2458 (6451 words)

	NEJM -- Bortezomib in Multiple Myeloma
		Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
		the cost-effectiveness of bortezomib in this letter is not correct.
		Economic evaluation of bortezomib (VELCADE) for relapsed and refractory multiple myeloma.
	content.nejm.org /cgi/content/full/353/12/1297 (695 words)

Try your search on: Qwika (all wikis)